28.07.2025





# **URGENT FIELD SAFETY NOTICE - Product Recall / Advisory Notice**

#### **Device Commercial Name:**

LinkSymphoKnee System, Tibial Component, Modular, Symmetric, Sz. 5, CoCrMo/TiNbN, cemented, Fixed:



Figure 1: Example images - LinkSymphoKnee TiNbN Tibial component, modular with security screws

#### For Attention of\*:

- ☑ Distributor / Local branch of manufacturer

# Contact details of local representative\*:

Waldemar Link GmbH & Co. KG

Responsible Person

Dr. Poroshat Khalilpour

Barkhausenweg 10

22339 Hamburg, Germany

E-Mail: vigilance@link-ortho.com

Tel. +49 (0)40 5 39 95 707

28 07 2025





# Risk addressed by FSN

#### 1. Information on Affected Device

### 1.1 Device Type\*:

LinkSymphoKnee, Tibial Component, Modular

# 1.2 Commercial name:

LinkSymphoKnee, Tibial Component, Modular, Symmetric, Sz. 5, CoCrMo/TiNbN, cemented. Fixed

### 1.3 Unique Device Identifier (EU UDI-DI):

04026575251278

# 1.4 Primary clinical purpose of device\*:

The non-active, surgically-invasive implantable LinkSymphoKnee manufactured by Waldemar Link GmbH & Co. KG is intended for long-term replacement of a diseased and / or defective knee joint in the human body.

The knee system forms a total replacement of the knee joint when combined with the femoral-, tibial- and polyethylene plateau. The LinkSymphoKnee can be used with fullgrown, anesthetized patients of any ethnic origin and sex. The LinkSymphoKnee can be implanted with and without cement. The implants may only be used and operated in an aseptic medical environment by people who have the required training, knowledge and experience in the orthopaedic and surgical field. The implants are supplied in sterile condition individually packed as single-use products.

Both the femoral and the tibial components are available in a monoblock and a modular version. In addition, there is a selection of femoral and tibial stems and augments, which can be used in conjunction with the modular version of the femoral and tibial components. All femoral and tibial metal components are offered with PorEx (TiNbN) surface modification. The PorEx coating is a ceramic-like surface modification and reduces the release of ions by up to 90 % (measured in static condition).

#### 1.5 Article number(s)\*:

880-100/50		

#### 1.6 Software version:

R I / A		
NI/A		
11///		

28.07.2025



# 1.7 Affected serial or lot number range:

210125/2259	
210125/2260	
210125/2261	
210125/2262	
210125/2263	
210125/2264	
210125/2265	
210125/2266	
210125/2267	
210125/2268	
210125/2269	
210125/2270	
210125/2271	
210125/2272	
210125/2273	

# 1.8 Associated devices:

N/A			

28.07.2025



# 2. Reason for Field Safety Corrective Action (FSCA)

## 2.1 Description of the product problem\*:

Due to a complaint we have been notified that a modular LinkSymphoKnee TiNbN Tibial Component was delivered with two uncoated security screws, which is incorrect. Two screws with TiNbN coating would be correct.




Figure 2: Example image of an incorrect uncoated security screw

### 2.2 Hazard giving rise to the FSCA\*:

If an uncoated screw is implanted, in the worst case there is a risk of irritation of the surrounding soft tissue due to a minimally increased release of ions from the implant materials.

# 2.3 Probability of problem arising:

The probability of consequences for the patient is to be classified as remote according to the assessments of specialists due to the small surface area of the affected screws (less than 0.5% of the overall surface area).

# 2.4 Predicted risk to patient/users:

See 2.2 and 2.3

# 2.5 Further information to help characterize the problem:

N/A

# 2.6 Background on Issue:

Waldemar Link received one complaint regarding a LinkSymphoKnee TiNbN Tibial Component, which was delivered with uncoated security screws. The uncoated screws have the same dimensions as the TiNbN coated screws.

#### 2.7 Other information relevant to FSCA:

212.22		
NI/A		
IV/A		
13//3		

28.07.2025



# LINK<sup>®</sup> W

# 3. Type of action to mitigate the risk

3.1 Action to be taken by user*:		
<ul> <li>☑ Identify Device</li> <li>☑ Quarantine Device</li> <li>☑ Return Device</li> <li>☐ Destroy Device</li> <li>☐ On-site device modification / inspection</li> <li>☐ Follow patient management recommendations</li> <li>☐ Take note of amendment / reinforcement of Instructions For Use (IFU)</li> <li>☐ Other</li> <li>☐ None</li> <li>Should you have any of the affected products in your inventory, please send the products back to Waldemar Link GmbH &amp; Co. KG.</li> <li>☐ Replacement will not incur any costs to you. Should you have any question on acquiring replacements for forthcoming surgeries, please contact your local sales representative or customer service for Link products.</li> <li>☐ Please return the reply form to us in any event until the 15.08.2025 as documentation of the recall. This applies even if you have none of the listed products in stock or if these products do not exhibit the defect in question.</li> <li>3.2 By when should the action be completed?:</li> <li>15.08.2025 — Return of customer reply form</li> <li>12.09.2025 — Return of products should be completed</li> </ul>		
3.3 Particular considerations for implantable de patients' previous results recommended?	vice. Is follow-up of patients of feview of	
☐ Yes, the following:	No, because:     Regular patient follow-up is sufficient. No additional follow-up is required, as no consequences are to be expected.	
3.4 Is customer Reply Required?*:		
⊠ Yes, until: <b>15.08.2025</b>	□ No	
3.5 Action being taken by the manufacturer:		
5.5 Action being taken by the manufacturer.		
<ul> <li>☑ Product Removal</li> <li>☐ On-site device modification / inspection</li> <li>☐ Software upgrade</li> <li>☐ IFU or labelling change</li> <li>☐ Other</li> <li>☐ None</li> </ul>		

28.07.2025





# 3.6 By when should the action be completed?

12.09.2025 – Retur 19.09.2025 – Revie 30.09.2025 – Plann	n of customer reply form n of products should be comp w of customer reply forms & p ed completion of FSCA d to be communicated to the p	product returns		
☐ Yes	⊠ No	□ N/A		
3.8 If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?				
□ appended to ⊠ not appended				

28.07.2025



# 4. General Information

4.1 FSN Type*:		
⊠ New	□ ∪	pdate
4.2 For updated FSN		
Reference number Date of previous F	of previous FSN: N/A SN: N/A	
4.3 For updated FSN,	, key new information as follows:	
N/A		
4.4 Further advice or	information already expected in	follow-up FSN?*:
□ Yes	⊠ No	□ Not planned yet
4.5 If follow-up FSN e	expected, what is the further advi	ce expected to relate to?:
N/A		
4.6 Anticipated times	cale for follow-up FSN:	
N/A		
4.7 Manufacturer info	rmation:	
Waldemar Link Gm Barkhausenweg 10 22339 Hamburg, G		
https://www.link-ort		0005215
	Regulatory) Authority of your cou	intry (EU) has been informed about this
⊠ Yes	□N	0
4.9 List of attachmen	ts/appendices:	
N/A		
4.10 Name/Signature:		

28.07.2025





# **Transmission of this Field Safety Notice**

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)

Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.

Note: Fields indicated by \* are considered necessary for all FSNs. Others are optional.